| Literature DB >> 27330384 |
Ashbala Khattak1, Fouad R Nakhli2, Hussam Mohammad Abdullatif Abouollo3.
Abstract
AIM: The aim of this study was to assess the effect of intracameral air on the endothelial cell morphometrics. PATIENTS AND METHODS: This is a retrospective controlled interventional cohort study of 26 patients (18 males and 8 females) who underwent unilateral deep anterior lamellar keratoplasty (DALK) for moderate keratoconus. The DALK patients were divided into two groups: a treatment group (14), which had micro perforations of the Descemet Membrane (DM) intraoperatively and received intracameral air at the end of the surgery; and an independent control group (12), which had no micro perforation and thus no intracameral air was injected. Postoperative best corrected visual acuity (BCVA), sphere, cylinder, spherical equivalent (SEQ), central corneal thickness, and endothelial cell morphometric features consisted of the endothelial cell density (ECD), polymegathism, and pleomorphism were compared between treatment and control groups.Entities:
Keywords: Endothelial cell density; Keratoconus; Keratoplasty; Pleomorphism; Polymegathism
Year: 2016 PMID: 27330384 PMCID: PMC4908048 DOI: 10.1016/j.sjopt.2016.01.003
Source DB: PubMed Journal: Saudi J Ophthalmol ISSN: 1319-4534
Figure 1The distribution of the best corrected visual acuity in the treatment and the control groups.
Figure 2The distribution of the spherical equivalent in the treatment and the control groups.
Figure 3The distribution of the endothelial cell density in the treatment and the control groups.
Comparison of the treatment and the control groups that had deep anterior lamellar keratoplasty.
| Parameter | Treatment group (intracameral air) | Control group (non-intracameral air) | Difference | 95% Confidence interval | ||
|---|---|---|---|---|---|---|
| Lower limit | Upper limit | |||||
| BCVA (LogMAR) | 0.36 ± 0.36 | 0.17 ± 0.11 | +0.19 | 0.810 | −0.03 | 0.42 |
| Sphere (D) | −5.14 ± 4.17 | −1.02 ± 3.29 | −4.12 | 0.011 | −7.20 | −1.04 |
| Cylinder (D) | −3.16 ± 2.20 | −2.88 ± 1.21 | −0.29 | 0.693 | −1.76 | 1.19 |
| SEQ (D) | −6.72 ± 4.66 | −2.46 ± 3.14 | −3.56 | 0.013 | −7.54 | −0.99 |
| CCT (μm) | 507.86 ± 62.69 | 525.67 ± 37.54 | −17.81 | 0.399 | −60.58 | 24.96 |
| ECD (cell/mm2) | 2176.76 ± 549.18 | 2257.30 ± 436.12 | −80.54 | 0.686 | −486.95 | 325.86 |
| Polymegathism (%) | 0.37 ± 0.06 | 0.31 ± 0.05 | +0.06 | 0.009 | 0.02 | 0.10 |
| Pleomorphism (%) | 0.48 ± .09 | 0.54 ± 0.10 | −0.06 | 0.139 | −0.13 | 0.02 |
Note: BCVA denotes best corrected visual acuity; SEQ denotes spherical equivalent; CCT denotes central corneal thickness; ECD denotes endothelial cell density.
Figure 4The distribution of the pleomorphism in the treatment and the control groups.
Figure 5The distribution of the polymegathism in the treatment and the control groups.
Postoperative refraction, central corneal thickness, and endothelium cell morphometrics post deep anterior lamellar keratoplasty (DALK) with and without Intracameral air injection for Descemet Membrane micro-perforation.
| Group | Case # | Age (year) | Gender | BCVA (LogMAR) | Sphere (D) | Cylinder (D) | SEQ (D) | CCT (μm) | ECD (cell/mm2) | Polymegathism (%) | Pleomorphism (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment group (intracameral air) | 1 | 30.8 | Female | 0.52 | −1.25 | −1.50 | −2.00 | 610 | 2538.10 | 49.40 | 41.00 |
| 2 | 31.5 | Female | 0.52 | −16.00 | −4.00 | −18.00 | 558 | 2208.00 | 34.60 | 51.70 | |
| 3 | 25.6 | Male | 0.15 | −2.50 | −2.75 | −3.88 | 551 | 2203.00 | 33.60 | 50.50 | |
| 4 | 44.0 | Male | 1.30 | −11.00 | −3.50 | −12.75 | 497 | 1649.50 | 34.00 | 62.00 | |
| 5 | 25.4 | Male | 0.81 | −6.00 | −1.00 | −6.50 | 460 | 2240.00 | 36.90 | 48.90 | |
| 6 | 28.9 | Male | 0.10 | −2.75 | −1.00 | −3.25 | 495 | 708.20 | 33.70 | 51.00 | |
| 7 | 23.2 | Male | 0.22 | −4.00 | −3.50 | −5.75 | 436 | 2580.70 | 43.00 | 48.00 | |
| 8 | 32.2 | Male | 0.15 | −5.00 | −1.50 | −5.75 | 367 | 2097.10 | 41.90 | 27.00 | |
| 9 | 37.7 | Female | 0.15 | −3.00 | −4.50 | −5.25 | 458 | 2820.70 | 31.00 | 55.00 | |
| 10 | 19.6 | Female | 0.10 | −2.00 | −2.00 | −3.00 | 548 | 2349.40 | 32.30 | 48.00 | |
| 11 | 25.6 | Male | 0.03 | −.50 | −3.25 | −2.13 | 529 | 1830.80 | 30.60 | 61.00 | |
| 12 | 31.5 | Female | 0.62 | −4.50 | −1.75 | −5.38 | 570 | 2711.10 | 39.90 | 39.00 | |
| 13 | 30.3 | Male | 0.02 | −5.75 | −4.50 | −8.00 | 506 | 1873.00 | 32.20 | 43.00 | |
| 14 | 36.2 | Female | 0.40 | −7.75 | −9.50 | −12.50 | 525 | 2665.00 | 40.90 | 52.00 | |
| Control group (non-intracameral air) | 1 | 18.4 | Male | 0.10 | −2.25 | −2.75 | −3.63 | 590 | 2623.80 | 27.70 | 54.00 |
| 2 | 25.6 | Male | 0.40 | −2.00 | −5.00 | −4.50 | 505 | 2228.00 | 35.60 | 51.00 | |
| 3 | 30.7 | Male | 0.30 | −2.00 | −1.00 | −2.50 | 481 | 1290.80 | 27.70 | 50.00 | |
| 4 | 21.9 | Male | 0.15 | .00 | −2.00 | −1.00 | 561 | 2189.60 | 30.80 | 54.00 | |
| 5 | 35.4 | Female | 0.22 | 6.50 | −4.25 | 4.38 | 491 | 2896.20 | 34.50 | 47.00 | |
| 6 | 17.0 | Male | 0.15 | −4.00 | −1.50 | −4.75 | 528 | 2822.80 | 22.50 | 59.00 | |
| 7 | 29.0 | Male | 0.15 | 1.25 | −4.50 | −1.00 | 557 | 1933.70 | 23.40 | 68.00 | |
| 8 | 28.0 | Male | 0.15 | .00 | −2.00 | −1.00 | 578 | 2149.30 | 26.60 | 55.00 | |
| 9 | 27.9 | Male | 0.05 | .00 | −3.00 | −1.50 | 516 | 2112.20 | 35.60 | 70.00 | |
| 10 | 18.2 | Male | 0.30 | −2.50 | −3.00 | −4.00 | 494 | 1973.80 | 35.00 | 53.00 | |
| 11 | 24.5 | Male | 0.05 | .00 | −2.50 | −1.25 | 485 | 2505.30 | 35.40 | 54.00 | |
| 12 | 19.4 | Female | 0.04 | −7.25 | −3.00 | −8.75 | 522 | 2362.10 | 34.70 | 33.00 | |
BCVA, best corrected visual acuity; SEQ, spherical equivalent; CCT, central corneal thickness; ECD, endothelium cell density.